Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
George K Ng
AddedFeb 19, 2024
UpdatedMay 31, 2026
George K Ng

George K Ng

Co-Founder, Iacta Pharmaceuticals

CrunchbaseLinkedInThe Org

George K Ng's Career

Iacta Pharmaceuticals
Iacta Pharmaceuticals

Irvine, CA, US

Co-Founder
Morphogenesis
Morphogenesis

Tampa, FL, US

Board Member· Board
Processa Pharmaceuticals
Processa Pharmaceuticals

Hanover, MD, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

George K Ng's Career

Iacta Pharmaceuticals
Iacta Pharmaceuticals
Pre-Seed$1M122016Irvine, CA, US
Co-Founder

Leadership at Iacta Pharmaceuticals

Damon BurrowsDamon BurrowsCo-Founder
William PedrantiWilliam PedrantiBoard Member

Similar to Iacta Pharmaceuticals

Eye-PharmaEye-PharmaLittle Rock, AR, USDrug Productsest. 2013Eye-PharmaLittle Rock, AR, US · est. 2013

Eye-Pharma, LLC: Innovating affordable ophthalmic drugs through reformulation in Little Rock, AR.

Seed · $145.5k7
Zhaoke Ophthalmology PharmaceuticalZhaoke Ophthalmology PharmaceuticalRhode Island, USPharmaceuticalsest. 2016Zhaoke Ophthalmology PharmaceuticalRhode Island, US · est. 2016

Zhaoke Ophthalmology: A leading platform in the pharmaceutical industry.

Public · $145M375
VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7
Iview TherapeuticsIview TherapeuticsDoylestown, PA, USDrug Developmentest. 2015Iview TherapeuticsDoylestown, PA, US · est. 2015

IVIEW Therapeutics: An ophthalmology-focused firm developing drugs for viral conjunctivitis treatment.

Series A · $55M30
Morphogenesis
Morphogenesis
Series B$47.3M81995Tampa, FL, US
Board Member· Board

Leadership at Morphogenesis

James A. Bianco, MDJames A. Bianco, MDCEO
Patricia LawsonPatricia LawsonCo-Founder
Michael LawmanMichael LawmanBoard Member

Similar to Morphogenesis

SpheringenicsSpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Pre-Seed · $730k4
ElevateBioElevateBioCambridge, MA, USCell Therapy, Gene Therapyest. 2017ElevateBioCambridge, MA, US · est. 2017

ElevateBio, a cell and gene therapy firm, develops and commercializes transformative medicines, swiftly turning R&D into viable therapies.

Series D · $1.2B375
Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
Processa Pharmaceuticals
Processa Pharmaceuticals
Public$15.6M142009Hanover, MD, US
CEO· C-Suite · Management

Leadership at Processa Pharmaceuticals

Khalid IslamKhalid IslamBoard Member
Wendy GuyWendy GuyCo-Founder
David YoungDavid YoungBoard Member
Patrick LinPatrick LinCo-Founder
Virgil D ThompsonVirgil D ThompsonBoard Member
Geraldine PannuGeraldine PannuBoard Member

George K Ng's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to George K Ng

Frank E. EmoryFrank E. EmoryBoard Member · ScanSourceIlya TikhonovIlya TikhonovCo-Founder · ArndaiJulia A NovinaJulia A NovinaCo-Founder · Nextrna TherapeuticsCheng ZhangCheng ZhangCo-Founder · Character BiosciencesSung OhSung OhCo-Founder · BruviKarah ParschauerKarah ParschauerBoard Member · Evolus